Provided by Tiger Trade Technology Pte. Ltd.

Merck

143.93
-0.7800-0.54%
Post-market: 143.930.00000.00%16:05 EDT
Volume:8.41M
Turnover:1.21B
Market Cap:355.10B
PE:113.08
High:145.90
Open:145.52
Low:143.68
Close:144.71
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:1.10
T/O Rate:0.34%
Dividend:3.36
Dividend Rate:2.33%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.47
PE(LYR):19.77

Loading ...

JPMorgan Adjusts Price Target on Merck to $140 From $135, Maintains Overweight Rating

MT Newswires Live
·
Jul 13

Merck & Co. Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Jul 11

Merck confirms FDA approves Keytruda combos with Padcev

TIPRANKS
·
Jul 11

FDA Approves Keytruda® (pembrolizumab) and Keytruda Qlex™ (pembrolizumab and Berahyaluronidase Alfa-pmph), Each with Padcev® (enfortumab Vedotin-ejfv), as Treatment Before and After Surgery for Adults with Muscle-invasive Bladder Cancer (mibc)

THOMSON REUTERS
·
Jul 11

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

MT Newswires Live
·
Jul 11

Merck's Keytruda Combination Wins Expanded FDA Approval for Muscle Invasive Bladder Cancer

MT Newswires Live
·
Jul 10

FDA approves Keytruda combos for certain muscle invasive bladder cancer cases

TIPRANKS
·
Jul 10

FDA Approves Pembrolizumab Combination for Muscle Invasive Bladder Cancer

Reuters
·
Jul 10

FDA: Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

THOMSON REUTERS
·
Jul 10

Berenberg Adjusts Price Target on Merck to $127 From $125, Keeps Hold Rating

MT Newswires Live
·
Jul 10

Merck & Co Inc : Berenberg Raises Target Price to $127 from $125

THOMSON REUTERS
·
Jul 10

Merck is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 10

Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK)

TIPRANKS
·
Jul 09

China's Sinopharm Held Strategic Cooperation Talks with Msd in Shanghai - Company Statement

THOMSON REUTERS
·
Jul 09

GSK Targets Pediatric Vaccine Growth With New Phase 3 Trial Against Merck’s ProQuad

TIPRANKS
·
Jul 09

Merck Likely to Post Inline Q2 Revenue, RBC Says

MT Newswires Live
·
Jul 08

Merck Price Target Maintained with a $142.00/share by RBC Capital

Dow Jones
·
Jul 08

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026

GlobeNewswire
·
Jul 08

Merck & Co Inc:

THOMSON REUTERS
·
Jul 08

Merck: Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations

THOMSON REUTERS
·
Jul 08